4168 Stock Overview
Engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GlycoNex Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$24.80 |
| 52 Week High | NT$31.85 |
| 52 Week Low | NT$24.00 |
| Beta | 0.85 |
| 11 Month Change | -6.94% |
| 3 Month Change | -9.49% |
| 1 Year Change | -12.37% |
| 33 Year Change | -8.99% |
| 5 Year Change | 22.77% |
| Change since IPO | -48.72% |
Recent News & Updates
Shareholder Returns
| 4168 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.4% | -1.0% | 0.8% |
| 1Y | -12.4% | 0.7% | 30.3% |
Return vs Industry: 4168 underperformed the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 4168 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 4168 volatility | |
|---|---|
| 4168 Average Weekly Movement | 2.4% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4168 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4168's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Mei-Chun Yang | www.glyconex.com.tw |
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology.
GlycoNex Incorporation Fundamentals Summary
| 4168 fundamental statistics | |
|---|---|
| Market cap | NT$2.68b |
| Earnings (TTM) | -NT$230.58m |
| Revenue (TTM) | NT$11.52m |
232.9x
P/S Ratio-11.6x
P/E RatioIs 4168 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4168 income statement (TTM) | |
|---|---|
| Revenue | NT$11.52m |
| Cost of Revenue | NT$5.13m |
| Gross Profit | NT$6.39m |
| Other Expenses | NT$236.97m |
| Earnings | -NT$230.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 55.47% |
| Net Profit Margin | -2,001.02% |
| Debt/Equity Ratio | 0% |
How did 4168 perform over the long term?
See historical performance and comparison